Weather New York, NY +68°F

allergan

CNBC Events

Investors Still Support Pfizer CEO After Failed Merger With Allergan

The company called off the acquisition of Allergan after the U.S. Treasury issued the rule preventing the deal. Nevertheless, Chief Executive Officer Ian Read still has the investors support.

Read Full Article
Pfizer Inc. Headquarters As They Agree To Combine With Allergan Plc In $160 Billion Deal

Pfizer and Allergan May Have to Call-Off Their $160 Billion Merger

Pfizer and Allergan will have to scrap the merger deal following the new regulation from Treasury Department to stop the U.S. company moving overseas.

Read Full Article
Teva Pharmaceutical Industries

Teva nears deal for Allergan's generic drugs unit: source

Teva Pharmaceutical Industries Ltd (TEVA.TA) is in advanced talks to buy Allergan Plc's (AGN.N) generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV (MYL.O), according to a person familiar with the matter.

Read Full Article
Valeant Pharmaceuticals International Inc.

Ackman's Pershing Square makes $3.3 billion bet on Valeant

Billionaire investor William Ackman has purchased a five percent stake in Valeant Pharmaceuticals (VRX.TO) (VRX.N), his hedge fund said on Monday, making him the Canadian drug company's fifth-largest stakeholder.

Read Full Article
Valeant Pharmaceuticals International Inc.

Valeant to drop deal-making in near term to cut debt, boost stock

Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

Read Full Article
Post and pre-injection medications sit on a shelf at a walk-in Botox salon in New York July 17, 2007.

Ackman's Pershing Square sees big payoff from Allergan deal

Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

Read Full Article
NYSE

S&P 500, Dow end at record highs, boosted by healthcare

The Dow and S&P 500 closed at record highs on Tuesday, lifted by further gains in healthcare shares and hopes for a stronger global economy.

Read Full Article
A sample of Botox

Allergan agrees to $66 billion Actavis offer; Valeant walks

Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

Read Full Article
David Pyott

Allergan near buyout of up to $65 billion to escape Valeant, Ackman: source

Allergan Inc is close to a buyout deal worth up to $65.5 billion by Actavis Plc, one that could end months of pursuit by Canada’s Valeant Pharmaceuticals and William Ackman's hedge fund, Pershing Square Capital Management, according to a person familiar with the matter.

Read Full Article
Post and pre-injection medications sit on a shelf at a walk-in Botox salon in New York July 17, 2007.

Allergan says has been approached by another party about a deal

Botox maker Allergan Inc (AGN.N), fighting a hostile takeover bid by Valeant Pharmaceuticals Inc (VRX.TO), said on Monday it was approached about a potential transaction by another party, identified as Actavis Plc (ACT.N) by a source familiar with the situation.

Read Full Article
A sample of Botox

Top Allergan holder Paulson urges deal with Shire: sources

Allergan Inc (AGN.N) shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc (SHP.L) as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc (VRX.TO), according to two people familiar with the matter.

Read Full Article
Amgen

Top investors push Salix to abandon Cosmo deal - sources

Some of the top 20 investors at Salix Pharmaceuticals Ltd (SLXP.O) are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA (COPN.S), and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

Read Full Article
Bill Ackman

Ackman, other shareholders ask Allergan to call special meeting

Investors owning 31 percent of shares of Allergan Inc have asked the company to call a special shareholder meeting, activist shareholder William Ackman said on Friday, giving the hedge fund manager a victory in his fight to acquire the Botox maker.

Read Full Article
Post and pre-injection medications sit on a shelf at a walk-in Botox salon in New York July 17, 2007.

Allergan to buy MAP Pharma for about $958 mln

U.S. specialty drugmaker Allergan Inc said late on Tuesday it will buy MAP Pharmaceuticals Inc for about $958 million in cash.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics